WINTER PARK, FL, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (Ticker: IMUN) announced today that Cytocom, Inc., a company that spun-off from Immune in 2014, is participating in Biotech Showcase Digital and H.C. Wainwright BioConnect. Both events will be held virtually and are scheduled alongside the J.P. Morgan 39th Annual Healthcare Conference 2021.
See the original post:
Immune Therapeutics Inc. Spinoff Cytocom, Inc. to Participate in Biotech Showcase and H.C. Wainwright BioConnect 2021 During “J.P. Morgan Week...
Related Post
- Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel - January 19th, 2021
- Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience - January 19th, 2021
- Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences - January 19th, 2021
- NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member - January 19th, 2021
- Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes - January 19th, 2021
- Bespoke Extracts Increases Conversion Price of Outstanding Discount Convertible Debentures - January 19th, 2021
- Neuropathix, Inc. Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant - January 19th, 2021
- Novan Provides Enrollment Update and Announces New Corporate Headquarters - January 19th, 2021
- Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer - January 19th, 2021
- Tauriga Sciences Inc. to Construct Product Showroom Within its New Corporate Headquarters - January 19th, 2021
- Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option - January 19th, 2021
- VIRBAC:2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) - January 19th, 2021
- Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference - January 19th, 2021
- Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer - January 19th, 2021
- Agenus to Participate in B. Riley Securities' Oncology Investor Conference - January 19th, 2021
- Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc. - January 19th, 2021
- Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration - January 19th, 2021
- Shockwave Medical to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021 - January 19th, 2021
- Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor / Equity Conference - January 19th, 2021
- Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein - January 19th, 2021
- Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure - January 17th, 2021
- Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update - January 17th, 2021
- SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones - January 17th, 2021
- PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-Oncology - January 17th, 2021
- Grey Cloak Tech Fuel4Thought™ Migraine Formula Results Published in World Journal of Advanced Research and Reviews - January 17th, 2021
- One World Pharma Receives Colombian Approval for Five THC Strains - January 17th, 2021
- Global Adoption of Biologicals Accelerates as Marrone Bio’s Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in... - January 17th, 2021
- RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing - January 17th, 2021
- Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference - January 17th, 2021
- Ceapro Inc. to Present at NobleCon17 - January 17th, 2021
- Tauriga Sciences Inc. Completes Payment for the Entirety of its Initial Production Run of its Caffeine Infused Version of Tauri-Gum - January 17th, 2021
- DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years - January 17th, 2021
- Dr. Han Myint Appointed as NextCure’s Chief Medical Officer - January 17th, 2021
- AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET - January 17th, 2021
- Global WholeHealth Partners, Corp (GWHP: OTC) Announces the Beginning Research for Saliva COVID 19 SARS 2 Antigen (N+S) Tests - January 17th, 2021
- Qilian International Holding Group Limited Announces Closing of Initial Public Offering - January 17th, 2021
- ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer - January 17th, 2021
- Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant... - January 17th, 2021
- TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference - January 16th, 2021
- Manager’s transactions - January 16th, 2021
- VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC - January 16th, 2021
- MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors - January 16th, 2021
- Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital - January 16th, 2021
- Motus GI Announces European Clearance of Enhanced Pure-Vu® GEN2 System to Harmonize with U.S. Configuration - January 16th, 2021
- Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer - January 16th, 2021
- Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17... - January 16th, 2021
- BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS)... - January 16th, 2021
- Golden Leaf Holdings Announces Oversubscribed Private Placement and increase in offering size - January 16th, 2021
- Aeterna Zentaris to Present at NobleCon17 - January 16th, 2021
- Tauriga Sciences Inc. Taking Immediate Steps to Strengthen its Board of Directors and Corporate Governance Protocols With Aim Towards Future Up-List... - January 16th, 2021
- Biomerica Reports Fiscal 2021 Second Quarter Financial Results and Provides Business Update - January 16th, 2021
- Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares - January 16th, 2021
- Tower One Provides Construction and Business Update for the Month of December 2020 - January 16th, 2021
- Valneva Announces Amendment to Deerfield and OrbiMed Debt Facility Terms - January 16th, 2021
- Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux - January 16th, 2021
- Emerald Bioscience to Change Name and Trading Symbol Effective Tuesday, January 19th - January 16th, 2021
- Muama Ryoko Reviews - Best 4G Wifi Router? - Product Review by Mike Vaughn - January 16th, 2021
- Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast - January 16th, 2021
- Tiziana Life Sciences to Present at Biotech Showcase Digital 2021 - January 12th, 2021
- Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee - January 12th, 2021
- Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021 - January 12th, 2021
- 22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company’s Reduced Nicotine Content Cigarettes - January 12th, 2021
- Myriad Genetics Forms Strategic Partnership with Illumina in Oncology - January 12th, 2021
- Alexis RIDEAU appointed CEO of DEINOVE - January 12th, 2021
- Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of... - January 12th, 2021
- Gilead holds 25.54% of Galapagos shares - January 12th, 2021
- GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - January 12th, 2021
- GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2020 - January 12th, 2021
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 12th, 2021
- EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues - January 12th, 2021
- Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene - January 12th, 2021
- Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference - January 12th, 2021
- INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium - January 12th, 2021
- IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant - January 12th, 2021
- Generation Bio Announces Closing of Public Offering - January 12th, 2021
- T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus - January 12th, 2021
- Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units - January 12th, 2021
- Women In Bio Elects Katie Williams, Associate Director of Business Development at Applied BioMath, as 2021 President-Elect - January 8th, 2021
- ExCellThera announces UM171 mechanism of action - January 8th, 2021
- Valneva Reports FY 2020 Cash of Over €200 Million - January 8th, 2021
Recent Comments